Journal article
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
SM de Boer, BG Wortman, T Bosse, ME Powell, N Singh, H Hollema, G Wilson, MN Chowdhury, L Mileshkin, J Pyman, D Katsaros, S Carinelli, A Fyles, CM McLachlin, C Haie-Meder, P Duvillard, RA Nout, KW Verhoeven-Adema, H Putter, CL Creutzberg Show all
Annals of Oncology | ELSEVIER | Published : 2018
Abstract
Background: In the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) with or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2). Pathology review was required before patient enrolment. The aim of this analysis was to evaluate the role of central pathology review before randomisation. Patients and methods: A total of 1295 cases underwent pathology review to confirm HR-EC in the Netherlands (n=395) and the UK (n=900), and for 1226/1295 (95%) matching review and original reports were available. In total, 329 o..
View full abstractGrants
Funding Acknowledgements
This work was supported by a grant from the Dutch Cancer Society (UL2006-4168/CKTO 2006-04), The Netherlands. The PORTEC-3 trial was supported in the UK by Cancer Research UK (C7925/A8659). This study is registered with ISRCTN (ISRCTN14387080, www.controlled-trials.com) and with ClinicalTrials.gov (NCT00 411138). The travel and stay in the UK for this project has been sponsored by the Leiden University Fund/van Steeden.